Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 15 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2025 vs. Q2 2025
How the institutions holding Oruka Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 81 | 105 | +24 |
| Shares | 34.4M | 45.6M | +11.1M (+32.3%) |
| Value | $386.0M | $875.8M | +$489.9M (+126.9%) |
New holders (32)
Institutions that held Oruka Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (8)
Institutions that held Oruka Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 583,327 | $6.54M |
| Silverarc Capital Management, LLC | 165,389 | $1.85M |
| Ikarian Capital, LLC | 68,574 | $768.7K |
| Susquehanna International Group, LLP | 33,962 | $380.7K |
| Boothbay Fund Management, LLC | 19,003 | $213.0K |
| Renaissance Technologies LLC | 13,900 | $155.8K |
| Millennium Management LLC | 12,326 | $138.2K |
| Caitong International Asset Management Co., Ltd | 1 | $11 |